Today we launched with an ambition to build the leading immune reset company. We are tackling immune-mediated diseases head-on by combining scientific expertise, a track record of advancing cell-depleting therapies through the clinic, and a robust pipeline. Special thanks to our investors for their commitment to this vision, including Monograph Capital, GSK, TPG, New Enterprise Associates (NEA), Norwest Venture Partners, Boyu Capital, UPMC Enterprises, LongRiver Investments and Keymed Biosciences. Read more about how we are defining the future of treatment for people with immune-mediated disease: https://lnkd.in/eMGg-q94
Ouro Medicines
生物技术研究
San Francisco，CA 1,136 位关注者
Defining the future of treatment for people with immune-mediated diseases
关于我们
Ouro Medicines is dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Our approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that enable durable remissions without ongoing immunosuppression for patients. Based in San Francisco, Ouro was founded by Monograph Capital in partnership with GSK. We are also backed by leading investors TPG, NEA, Norwest and more.
- 网站
-
www.ouromedicines.com
Ouro Medicines的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Francisco，CA
- 类型
- 私人持股
- 创立
- 2024
地点
-
主要
获取路线
US，CA，San Francisco